BioVie (NASDAQ: BIVI) director awarded 57,500 stock options at $1.31

Rhea-AI Filing Summary

BioVie Inc. director Amy Suzon Chappell reported receiving a stock option grant on January 5, 2026. The award covers options to purchase 57,500 shares of BioVie common stock at an exercise price of $1.31 per share, with no cash paid for the grant itself.

According to the vesting terms, 7,500 shares underlying the options vest on the grant date. The remaining options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and on the earlier of November 11, 2026 and the date of BioVie’s 2026 annual shareholders’ meeting. The options expire on January 5, 2031 if not exercised.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chappell Amy Suzon

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	57,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 57,500 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chappell Amy Suzon

(Last) (First) (Middle)

C/O BIOVIE INC.

680 W NYE LANE STE 201

(Street)

CARSON CITY NV 89703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOVIE INC. [ BIVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.31	01/05/2026		A		57,500		(1)	01/05/2031	Common Stock	57,500	$0	57,500	D

Explanation of Responses:

1. 7,500 shares underlying the options vest on grant date and the remaining balance will vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting.

	/s/ Joanne Wendy Kim, attorney-in-fact for Amy Suzon Chappell	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BioVie Inc. (BIVI) disclose in this Form 4 filing?

The filing reports that director Amy Suzon Chappell received a grant of stock options covering 57,500 shares of BioVie Inc. common stock on January 5, 2026.

What are the key terms of Amy Suzon Chappell’s BioVie (BIVI) stock options?

The options give her the right to buy 57,500 shares of BioVie common stock at an exercise price of $1.31 per share, with an expiration date of January 5, 2031.

How do the BioVie (BIVI) stock options granted to Amy Suzon Chappell vest?

7,500 shares underlying the options vest on the grant date, and the remaining balance vests in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026 and the date of BioVie’s 2026 annual shareholders’ meeting.

Is the BioVie (BIVI) Form 4 transaction a purchase or a grant?

It is a grant of a derivative security: stock options described as a "Stock Option (right to buy)," reported with transaction code "A" for an acquisition.

How many BioVie (BIVI) derivative securities does Amy Suzon Chappell own after this transaction?

Following the reported transaction, she beneficially owns 57,500 derivative securities (stock options), held with direct ownership.

Does this BioVie (BIVI) Form 4 indicate any sale of shares by Amy Suzon Chappell?

No. The Form 4 shows an acquisition of stock options (transaction code "A") and does not report any sale or disposition of BioVie common shares.